Cessation in Mental Illness integrates tobacco, vaping, and nicotine treatment into psychiatric care so symptom relief and cardiometabolic health advance together. This page translates evidence into clinic workflows—universal screening, “opt-out” offers of help, and tailored quit plans for people living with depression, anxiety, bipolar disorder, psychosis, and SUD. If you’re comparing an addiction cessation conference, you’ll find stepped pathways that combine behavioral support with pharmacotherapy (NRT, varenicline, bupropion) while protecting sleep and mood. Stigma-free messaging, practical problem solving, and parity-aligned policies help teams close the mortality gap driven by commercial tobacco and nicotine products.

Real-world success depends on timing, dose, and follow-through. Quit attempts align with medication reviews, pain and sleep plans, and relapse-prevention scripts; varenicline or combination NRT address high dependence, while bupropion supports mood and attention when appropriate. We emphasize harm-reduction on the way to abstinence—clean nicotine, fewer triggers, and contingency plans for stress peaks. Staff training, pharmacy partnerships, and ePRO dashboards keep momentum visible, and warm handoffs to peers and quitlines extend reach beyond clinic walls. For policy and population strategies, see Global Tobacco Control, which complements this page’s focus on bedside implementation.